Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study involving women undergoing taxane-based chemotherapy, a twice-daily topical application of BPM31543 was well-tolerated and showed potential in reducing severe hair loss, prompting further investigation at higher doses.

This study found that ursolic acid at 50 mg/kg improved biochemical, hormonal, and ovarian histopathological markers in a rat model of PCOS, suggesting its potential as a therapeutic option.

This randomized, controlled clinical trial found that combining 25 mg/d bicalutamide with 1 mg/d minoxidil for 24 weeks did not enhance hair density improvement in female pattern hair loss compared to 1 mg/d minoxidil alone, with no significant difference observed between the groups.

This study concluded that combined hormonal contraceptives containing desogestrel, drospirenone, or cyproterone acetate were associated with a higher risk of venous thromboembolism compared to those containing levonorgestrel.

This source describes clascoterone, a new topical treatment for acne vulgaris that blocks androgen receptors to reduce sebaceous gland activity and inflammation, offering a lower risk of systemic side effects compared to oral treatments.

This source explores the potential use of oral bicalutamide for treating female pattern hair loss, but specific results or outcomes from the study are not reported in the abstract.

In this study, a risk score was developed and validated to identify patients at high risk of clinical failure after femoropopliteal peripheral vascular intervention, aiming to guide the selection of patients who may benefit from paclitaxel-coated devices or alternative strategies.

This study found that rapidly administered intravenous cimetidine may cause a significant drop in blood pressure in critically ill patients, whereas ranitidine does not appear to have the same effect.

The authors concluded that pegylated liposomal doxorubicin may offer comparable efficacy to conventional doxorubicin with reduced toxicity in metastatic breast cancer treatment.

This study found that Litfulo improved hair regrowth in patients aged 12 and older with severe alopecia areata but did not meaningfully improve anxiety or depression symptoms compared to placebo.

In this study, researchers found that the compound BMS-470539 induced a senescence-like state in fibroblasts from systemic sclerosis patients, reducing fibrosis-associated markers in vitro and decreasing skin thickness in a mouse model of skin fibrosis, suggesting a novel therapeutic strategy for managing fibroblast-driven diseases.

This study found that self-monitoring blood pressure among pregnant women with hypertension did not significantly improve clinical outcomes compared to usual care, though women reported positive cognitive and emotional responses.

This study found that a regimen combining cyproterone acetate and testosterone buciclate induced reversible azoospermia in bonnet monkeys, highlighting its potential as an effective male contraceptive.

This study found that self-reported use of finasteride or oral contraceptives did not reduce the incidence of renal cancer in participants of the PCLO trial.

This review details how baricitinib successfully demonstrated significant hair regrowth in clinical trials for severe alopecia areata, now leading to its approval as the first systemic therapy for the condition, while also highlighting the importance of assessing individual risk factors for adverse events.

This phase 3 trial found that over 50% of adolescents with severe alopecia areata achieved successful hair regrowth after 52 weeks on baricitinib 4-mg, with no new safety concerns reported compared to existing safety profiles.

In a retrospective clinical study, this research found that baricitinib is effective for alopecia areata, with 42.3% of patients achieving a significant reduction in hair loss by week 36, and 52.4% by week 52, outperforming previous trials.

In this study, bicalutamide at low doses was not linked to significant liver enzyme changes compared to other androgen-blocking treatments in transfeminine adolescents and young adults, suggesting its safety with careful monitoring for this population over one year.

This study found that the progestins norgestimate and dienogest may help treat clinical hyperandrogeny in women by inhibiting skin 5 alpha-reductase activity with minimal androgenic potential.

This study found that treatment with ritlecitinib or brepocitinib was effective in improving scalp hair loss for patients with alopecia areata over 24 weeks compared to placebo.

This study reports that ritlecitinib was prescribed to a diverse group of patients, including adolescents and adults with and without prior treatment for Alopecia Areata, in the first three months after FDA approval, potentially expanding care options for this condition.

This study aims to compare the safety and effectiveness of bariatric surgery versus medical care on ovulation rates in women with PCOS and obesity, as current observational data suggests surgery may improve fertility prospects, but no randomized trial has yet confirmed this effect.

This study found that among adolescents with alopecia areata and significant hair loss, treatment with ritlecitinib resulted in greater hair regrowth and self-reported improvement compared to placebo over 48 weeks, with common side effects including headache, acne, and nasopharyngitis.

In this study, researchers found that the novel gene circCFAP20DC enhances the proliferation of goat follicular granulosa cells by activating the RB pathway, facilitating their progression from the G1 to S phase during follicular development.

This study found that ritlecitinib, approved for alopecia areata in patients aged 12 and older, has an acceptable safety profile with mild to moderate side effects and no increase in serious adverse events compared to placebo.

Bicalutamide may improve hair growth in postmenopausal women with mild side effects.

In this study, baicalin from Scutellaria baicalensis decreased androgen levels in both cells and PCOS model rats by inhibiting key gene expression, suggesting it may be a potential treatment for hyperandrogenism in PCOS.

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

Baricitinib helps with early hair regrowth in people with alopecia areata.